论文部分内容阅读
徐文怀教授大肠癌病人根治术后仍有约40%于5年内死于复发和转移。因此,化学治疗在大肠癌综合治疗中具有重要地位,主要用于:①晚期病例。②术后复发和转移病人。③根治手术后辅助性化疗。常用化疗药物有氟脲嘧啶(5-FU),自1956年Roche公司首创性地合成开发以来,其一直是消化道肿瘤化疗首选药物。5-FU在体内可转变为5-氟脲嘧啶脱氧核苷,可抑制胸腺嘧啶核苷合成酶,阻断脲嘧啶脱氧核苷转变为胸腺嘧啶脱氧核苷,从而影响DNA的合成。5-FU治疗大肠癌的有效率为11%～20%,缓解期约4～9个月,对腹部病灶、淋巴结转移和肝转移效果较好。5-FU衍生物的口服剂型FT_(207)、UFT、UCFU(Carmofur)通过肝内药物代谢酶P-450及在体内自然分解转化为5-FU而发挥作用。近几年来国内外
Professor Xu Wenhuai still has about 40% of patients with colorectal cancer died of recurrence and metastasis within 5 years after radical resection. Therefore, chemotherapy has an important position in the comprehensive treatment of colorectal cancer, mainly used for: 1 advanced cases. 2 postoperative recurrence and metastasis. 3 radical surgery adjuvant chemotherapy. The commonly used chemotherapeutic drug is 5-fluorouracil (5-FU). Since Roche’s first synthetic synthesis in 1956, it has been the first choice for chemotherapy for digestive tract cancer. 5-FU can be converted into 5-fluorouracil deoxyriboside in vivo, which can inhibit thymidine synthase and block the conversion of uracil deoxynucleotide into thymidine, which affects DNA synthesis. The effective rate of 5-FU for colorectal cancer is 11% to 20%, and the remission period is about 4 to 9 months. The effect on the abdominal lesions, lymph node metastasis, and liver metastasis is better. Oral formulations of 5-FU derivatives, FT_ (207), UFT, and UCFU (Carmofur), function through intrahepatic drug metabolizing enzymes P-450 and natural breakdown into 5-FU in the body. In recent years at home and abroad